Kymera Therapeutics, Inc. (KYMR) — 8-K Filings

8-K Filings (16)

• 8-K Filing — Dec 10, 2025
• Kymera Therapeutics Files 8-K — Dec 8, 2025 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on December 8, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, o
• Kymera Therapeutics Files 8-K on Officer/Director Changes — Sep 3, 2025 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on August 27, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of ce
• Kymera Therapeutics Reports Shareholder Vote Matters — Jun 27, 2025 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders on June 25, 2025. The filing details the c
• Kymera Therapeutics Files 8-K — Jun 25, 2025 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on June 25, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other
• Kymera Therapeutics Files 8-K — Jun 2, 2025 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on June 2, 2025, reporting on events including Regulation FD disclosures, other events, and financial statements. The com
• Kymera Therapeutics Files 8-K — May 9, 2025 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on May 9, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial S
• Kymera Therapeutics Announces Executive and Board Changes — Mar 3, 2025 Risk: medium
  Kymera Therapeutics, Inc. announced on March 3, 2025, changes in its executive team and board of directors. The filing details the departure of certain officers
• Kymera Therapeutics Files 8-K — Feb 27, 2025 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on February 27, 2025, reporting on results of operations and financial condition, director/officer changes, and financial
• Kymera Therapeutics Files 8-K — Jan 14, 2025 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on January 14, 2025, reporting its corporate information. The company, incorporated in Delaware with its principal execut
• Kymera Therapeutics Enters Material Definitive Agreement — Aug 20, 2024 Risk: medium
  Kymera Therapeutics, Inc. announced on August 19, 2024, that it entered into a material definitive agreement. The company also reported other events and filed f
• Kymera Therapeutics Files 8-K — Jul 8, 2024 Risk: low
  Kymera Therapeutics, Inc. filed an 8-K on July 8, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other
• Kymera Therapeutics Files 8-K on Officer/Director Changes — Jun 20, 2024 Risk: medium
  Kymera Therapeutics, Inc. filed an 8-K on June 20, 2024, reporting events that occurred on June 18, 2024. The filing indicates changes related to the departure
• Kymera Therapeutics Appoints New CMO, Adds Directors — Apr 1, 2024 Risk: medium
  Kymera Therapeutics, Inc. announced on March 28, 2024, the appointment of Dr. Nabeel K. Sarwar as Chief Medical Officer and the election of Dr. Nabeel K. Sarwar
• Kymera Therapeutics Reports Material Agreement, Financial Condition Changes — Jan 5, 2024
  Kymera Therapeutics, Inc. filed an 8-K on January 5, 2024, reporting an event that occurred on January 4, 2024, concerning an "Entry into a Material Definitive
• Kymera to Present at J.P. Morgan Healthcare Conference Jan 9 — Jan 4, 2024
  Kymera Therapeutics, Inc. filed an 8-K on January 4, 2024, to announce that they will be participating in the 42nd Annual J.P. Morgan Healthcare Conference on J

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX